Israeli personalized cancer therapy company OncoHost, announced on Tuesday that it raised $35 million in a Series C funding round to finance its multicenter PROPHETIC trial that tests the company’s machine-learning-based host response profiling platform PROphet, a precision oncology diagnostic solution.  The funding will also be used to support the company’s commercial launch, which is […]

To mark World Cancer Day, we've highlighted some innovative strategies for cancer therapy developed in Israel.

OncoHost's platform combines proteomic analysis with AI to predict host responses to immunotherapy, and gain insight into cancer treatments.